Can you get medical cannabis for chronic pain in the UK?

Chronic non-cancer pain — long-term back pain, neck pain, widespread musculoskeletal pain — is the single most common reason people are prescribed medical cannabis privately in the UK. It is also the condition where NICE has looked at the evidence and recommended against it. Holding both facts together is the honest starting point.

Is chronic pain treated with medical cannabis in the UK?

Yes, in private practice, and more often than any other condition. No, as a routine NHS treatment — no cannabis-based medicine is licensed for chronic non-cancer pain in the UK, and NICE guideline NG144 recommends against offering one outside a clinical trial.

The gap between those two sentences is the whole story. NICE assessed whether the NHS should offer these medicines to a population of chronic pain patients and concluded the evidence did not support it. That guidance does not remove a specialist's legal ability to prescribe an unlicensed medicine to an individual with unmet clinical need. Private prescribing occupies that space, and the honest framing for it is a supervised trial in someone who has run out of better options — not an established treatment.

In practice this covers long-term back and neck pain, widespread musculoskeletal pain, post-surgical pain that never settled, and pain that no longer has a clear structural explanation. If your pain is specifically nerve pain, see neuropathic pain, where the evidence has been studied separately.

What the evidence actually shows

Randomised trial evidence in chronic non-cancer pain is thin, mostly short, and mostly small. The larger body of UK data is observational — real-world outcomes from patients already being treated, which cannot separate the medicine from expectation, natural fluctuation, or the effect of finally being taken seriously.

The UK Medical Cannabis Registry, run through a UK clinic and analysed by researchers at Imperial College London, has published outcomes for chronic pain patients showing improvements in pain-specific scores and health-related quality of life, with mostly mild-to-moderate side effects. The authors are explicit that causation cannot be inferred from this kind of study, and that randomised trials are still needed. That is the state of the field: encouraging signals, no proof.

Read alongside it the NICE conclusion, which is drawn from the same literature and reaches a different conclusion because it is answering a different question. We unpack that tension in Can medical cannabis treat my condition?

What a specialist will want to see

There is no UK list of qualifying conditions, so nothing here entitles you to a prescription. A specialist works through your history and decides whether a monitored trial is justified for you. For chronic pain they will typically look at:

• How long the pain has lasted, where it is, and whether there is a diagnosis behind it
• Which standard treatments you have tried — typically at least two — and why each was stopped or judged inadequate
• Whether you are on opioids, gabapentinoids, antidepressants or benzodiazepines, and at what doses
• What you actually want to change: pain scores, sleep, function, or reducing another medicine
• Your personal and family history of psychosis, and your current mental health
• Whether you drive, and whether you work in a safety-critical role

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

The common side effects are dizziness, drowsiness, dry mouth, appetite changes and difficulty concentrating. THC-containing products can impair driving, and it is an offence to drive while impaired even with a valid prescription.

A specialist is likely to decline, or to proceed only with a very cautious plan, if you have a personal or family history of psychosis or schizophrenia, an unstable serious mental illness, significant cardiovascular disease, or if you are pregnant or breastfeeding. High-dose opioid use alongside cannabis-based medicines needs care rather than an automatic no.

Chronic pain is also the condition where expectations most often outrun what the medicine can do. A realistic target is a modest improvement in pain and function that makes the side effects worth it — not the disappearance of pain.

How medical cannabis is thought to help

The body has its own endocannabinoid system — a network of signalling molecules and receptors that helps regulate how pain is processed, alongside sleep, mood, appetite and inflammation. Cannabis-based medicines contain compounds that interact with this system, and the working theory is that they may modulate the amplified, persistent pain signalling that characterises many long-term pain conditions.

It is worth being precise about what that does and does not mean. A plausible mechanism is not the same as proof of benefit for any individual, and the two main compounds are thought to act quite differently — one is psychoactive and more associated with pain and sleep effects, the other is not intoxicating and is often discussed for its calming and anti-inflammatory properties. In practice a specialist chooses and balances these based on your symptoms and your tolerance of side effects. If you want the underlying biology in plain terms, see the endocannabinoid system explained and THC and CBD explained.

What treatment involves in practice

If a specialist decides a trial is justified, treatment almost always starts at a low dose and is increased slowly under supervision. This cautious titration lets you and your clinician find the smallest amount that helps while keeping side effects manageable, and it is why the first weeks are about adjustment rather than a fixed prescription.

The usual formats are oils or capsules taken by mouth, which act more slowly and last longer, and dried flower for vaporising, which acts faster but wears off sooner. Neither is smoked; vaporising heats the material without burning it. How these are taken, and why the route matters, is covered in how cannabis-based medicines are taken, and the way a starting point is chosen and changed is set out in how a dose is decided and adjusted.

Follow-up reviews are part of the plan, not an optional extra. At each review your specialist checks whether pain, sleep and daily function have improved, weighs that against any side effects, and adjusts the product or dose — or recommends stopping if the balance is not in your favour. Living with a prescription day to day also raises practical questions about driving, work and drug testing, and travelling abroad, each of which is covered in its own guide rather than restated here.

Questions worth asking your specialist

A good assessment goes both ways. Because chronic pain sits in the space where evidence is weakest and expectations are often highest, it is worth arriving with questions that keep the plan honest and specific to you.

• Given my particular pain and history, what realistic improvement should I aim for?
• What would tell us this is working, and at what point would we agree to stop?
• Which format do you suggest starting with, and why that one for me?
• How will this interact with the medicines I already take, including any opioids?
• What side effects should I expect early on, and which ones mean I should call you?
• How will my GP be kept informed, and does shared care apply?

If you want to take this further

The useful next step is a proper assessment, not a better list. Gather your diagnosis, the treatments you have already tried and what happened with each, and your current medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If chronic pain is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Patient guide · Written by the Flora House editorial team · Last reviewed: 7 October 2026